Pomerantz Law Firm Investigates Securities Fraud Claims Against Replimune Group, Inc.

Investor Alert: Replimune Group, Inc.

The Pomerantz Law Firm has announced an investigation into possible claims from investors of Replimune Group, Inc. (NASDAQ: REPL). This investigation aims to determine whether the company, along with certain officers and directors, has participated in securities fraud or engaged in other illegal business activities that could have impacted investors.

On July 22, 2025, Replimune released a press statement notifying the public that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding the company's Biologics License Application (BLA) for its treatment RP1 (vusolimogene oderparepvec) in combination with nivolumab, intended for patients suffering from advanced melanoma.

According to the FDA press release, the CRL indicated that the agency could not approve the application in its current form. The agency raised concerns about the IGNYTE trial, stating it did not meet the standards of a well-controlled clinical investigation, which is necessary to establish effectiveness. Furthermore, the FDA highlighted that the trial was hard to interpret because of the diverse nature of the patient population involved. It also specified that issues related to the trial's design need to be rectified, including the contribution of various components; however, it’s worth noting that no safety problems were reported.

Following this disappointing announcement, Replimune's stock price drastically dropped by $9.52 per share, representing a 77.24% decline, bringing the closing price down to $2.81 per share on the same day. This significant decrease raises concerns among investors regarding the health and future viability of the company, as well as the legality of the practices in question.

The Pomerantz Law Firm, known for its expertise in corporate, securities, and antitrust litigation, has a rich history of advocating for victims of securities fraud and corporate misconduct. Established over 80 years ago by Abraham L. Pomerantz, the firm has recuperated significant damages for many class members and continues to pursue justice for affected investors with vigor.

If you are an investor in Replimune Group, you are advised to reach out to Danielle Peyton at [email protected] or by calling 646-581-9980, ext. 7980 for guidance on how to join the ongoing investigation or participate in the class action lawsuit.

The outcome of this investigation could have serious implications not only for the affected investors but also for how Replimune navigates regulatory requirements and market expectations moving forward. Keep an eye on developments as they unfold, as they may provide critical insights and updates pertinent to your investment.

For additional information about the Pomerantz Law Firm and its ongoing work in the field of securities class actions, you may access their website at www.pomerantzlaw.com.

This article does not constitute legal advice, and past results do not guarantee similar outcomes in future cases.